{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:21:54Z","timestamp":1794604914450,"version":"4.9.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Treatment with immune checkpoint blockade (CPB) therapies often leads to prolonged responses in patients with metastatic melanoma, but the common mechanisms of primary and acquired resistance to these agents remain incompletely characterized and have yet to be validated in large cohorts. By analyzing longitudinal tumor biopsies from 17 metastatic melanoma patients treated with CPB therapies, we observed point mutations, deletions or loss of heterozygosity (LOH) in beta-2-microglobulin (\n                    <jats:italic>B2M<\/jats:italic>\n                    ), an essential component of MHC class I antigen presentation, in 29.4% of patients with progressing disease. In two independent cohorts of melanoma patients treated with anti-CTLA4 and anti-PD1, respectively, we find that\n                    <jats:italic>B2M<\/jats:italic>\n                    LOH is enriched threefold in non-responders (~30%) compared to responders (~10%) and associated with poorer overall survival. Loss of both copies of\n                    <jats:italic>B2M<\/jats:italic>\n                    is found only in non-responders.\n                    <jats:italic>B2M<\/jats:italic>\n                    loss is likely a common mechanism of resistance to therapies targeting CTLA4 or PD1.\n                  <\/jats:p>","DOI":"10.1038\/s41467-017-01062-w","type":"journal-article","created":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T06:37:37Z","timestamp":1508481457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":967,"title":["Resistance to checkpoint blockade therapy through inactivation of antigen presentation"],"prefix":"10.1038","volume":"8","author":[{"given":"Moshe","family":"Sade-Feldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxin J.","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Barzily-Rokni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Eliane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey L.","family":"Bjorgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Vitzthum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna M.","family":"Blackmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennie T.","family":"Frederick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehlika","family":"Hazar-Rethinam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4690-5978","authenticated-orcid":false,"given":"Brandon A.","family":"Nadres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily E.","family":"Van Seventer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachet A.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Yizhak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rosebrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2528-1446","authenticated-orcid":false,"given":"Dimitri","family":"Livitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Adalsteinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-0753","authenticated-orcid":false,"given":"Gad","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn M.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan B.","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Stemmer-Rachamimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve M.","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan A.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith T.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Hacohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,26]]},"reference":[{"key":"1062_CR1","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. \n                           372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1062_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber, J. S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. \n                           16, 375\u2013384 (2015).","journal-title":"Lancet Oncol."},{"key":"1062_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature \n                           515, 563\u2013567 (2014).","journal-title":"Nature"},{"key":"1062_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer \n                           12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"1062_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. \n                           8, 328rv324 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1062_CR6","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","volume":"44","author":"MK Callahan","year":"2016","unstructured":"Callahan, M. K., Postow, M. A. & Wolchok, J. D. Targeting T cell co-receptors for cancer therapy. Immunity \n                           44, 1069\u20131078 (2016).","journal-title":"Immunity"},{"key":"1062_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.tibs.2013.06.003","volume":"38","author":"S Hulpke","year":"2013","unstructured":"Hulpke, S. & Tampe, R. The MHC I loading complex: a multitasking machinery in adaptive immunity. Trends Biochem. Sci. \n                           38, 412\u2013420 (2013).","journal-title":"Trends Biochem. Sci."},{"key":"1062_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science \n                           350, 207\u2013211 (2015).","journal-title":"Science"},{"key":"1062_CR9","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. \n                           371, 2189\u20132199 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1062_CR10","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","volume":"34","author":"AI Daud","year":"2016","unstructured":"Daud, A. I. et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J. Clin. Oncol. \n                           34, 4102\u20134109 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1062_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao, J. et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell \n                           167, 397\u2013404 (2016).","journal-title":"Cell"},{"key":"1062_CR12","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. \n                           375, 819\u2013829 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1062_CR13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis, E. et al. A landscape of driver mutations in melanoma. Cell \n                           150, 251\u2013263 (2012).","journal-title":"Cell"},{"key":"1062_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell \n                           165, 35\u201344 (2016).","journal-title":"Cell"},{"key":"1062_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12105","volume":"1284","author":"MD Vesely","year":"2013","unstructured":"Vesely, M. D. & Schreiber, R. D. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann. N. Y. Acad. Sci. \n                           1284, 1\u20135 (2013).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1062_CR16","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature \n                           515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"1062_CR17","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/ijc.22691","volume":"121","author":"M Kloor","year":"2007","unstructured":"Kloor, M. et al. Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int. J. Cancer \n                           121, 454\u2013458 (2007).","journal-title":"Int. J. Cancer"},{"key":"1062_CR18","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00262-012-1321-6","volume":"61","author":"M Bernal","year":"2012","unstructured":"Bernal, M., Ruiz-Cabello, F., Concha, A., Paschen, A. & Garrido, F. Implication of the beta2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunol. Immunother. \n                           61, 1359\u20131371 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"1062_CR19","doi-asserted-by":"publisher","first-page":"13140","DOI":"10.1073\/pnas.94.24.13140","volume":"94","author":"A Porgador","year":"1997","unstructured":"Porgador, A., Mandelboim, O., Restifo, N. P. & Strominger, J. L. Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc. Natl Acad. Sci. USA \n                           94, 13140\u201313145 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1062_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-immunol-032712-095951","volume":"31","author":"DH Raulet","year":"2013","unstructured":"Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W. & Jung, H. Regulation of ligands for the NKG2D activating receptor. Annu. Rev. Immunol. \n                           31, 413\u2013441 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"1062_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/jnci\/88.2.100","volume":"88","author":"NP Restifo","year":"1996","unstructured":"Restifo, N. P. et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl Cancer Inst. \n                           88, 100\u2013108 (1996).","journal-title":"J. Natl Cancer Inst."},{"key":"1062_CR22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","volume":"20","author":"M Challa-Malladi","year":"2011","unstructured":"Challa-Malladi, M. et al. Combined genetic inactivation of beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell \n                           20, 728\u2013740 (2011).","journal-title":"Cancer Cell"},{"key":"1062_CR23","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature11071","volume":"485","author":"MF Berger","year":"2012","unstructured":"Berger, M. F. et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature \n                           485, 502\u2013506 (2012).","journal-title":"Nature"},{"key":"1062_CR24","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1189\/jlb.71.6.907","volume":"71","author":"FH Igney","year":"2002","unstructured":"Igney, F. H. & Krammer, P. H. Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukoc. Biol. \n                           71, 907\u2013920 (2002).","journal-title":"J. Leukoc. Biol."},{"key":"1062_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00251-010-0494-4","volume":"63","author":"I Maleno","year":"2011","unstructured":"Maleno, I. et al. Frequent loss of heterozygosity in the beta2-microglobulin region of chromosome 15 in primary human tumors. Immunogenetics \n                           63, 65\u201371 (2011).","journal-title":"Immunogenetics"},{"key":"1062_CR26","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1056\/NEJMoa1403352","volume":"371","author":"N Wagle","year":"2014","unstructured":"Wagle, N. et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N. Engl. J. Med. \n                           371, 1426\u20131433 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1062_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-1-r1","volume":"12","author":"S Fisher","year":"2011","unstructured":"Fisher, S. et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol. \n                           12, R1 (2011).","journal-title":"Genome Biol."},{"key":"1062_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics \n                           29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"1062_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics \n                           12, 323 (2011).","journal-title":"BMC Bioinformatics"},{"key":"1062_CR30","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature \n                           471, 467\u2013472 (2011).","journal-title":"Nature"},{"key":"1062_CR31","first-page":"1811","volume-title":"Bioinformatics","author":"CT Saunders","year":"2012","unstructured":"Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics \n                           28, 1811\u20131817 (2012)."},{"key":"1062_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw227","volume":"44","author":"Z Lai","year":"2016","unstructured":"Lai, Z. et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. \n                           44, e108 (2016).","journal-title":"Nucleic Acids Res."},{"key":"1062_CR33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. \n                           31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"1062_CR34","doi-asserted-by":"publisher","first-page":"E2423","DOI":"10.1002\/humu.22771","volume":"36","author":"AH Ramos","year":"2015","unstructured":"Ramos, A. H. et al. Oncotator: cancer variant annotation tool. Hum. Mutat. \n                           36, E2423\u2013E2429 (2015).","journal-title":"Hum. Mutat."},{"key":"1062_CR35","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. \n                           30, 413\u2013421 (2012).","journal-title":"Nat. Biotechnol."},{"key":"1062_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0602-8","volume":"16","author":"AG Deshwar","year":"2015","unstructured":"Deshwar, A. G. et al. PhyloWGS: reconstructing subclonal composition and evolution from whole-genome sequencing of tumors. Genome Biol. \n                           16, 35 (2015).","journal-title":"Genome Biol."},{"key":"1062_CR37","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/nbt.3344","volume":"33","author":"SA Shukla","year":"2015","unstructured":"Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. \n                           33, 1152\u20131158 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1062_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00251-008-0341-z","volume":"61","author":"I Hoof","year":"2009","unstructured":"Hoof, I. et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics \n                           61, 1\u201313 (2009).","journal-title":"Immunogenetics"},{"key":"1062_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. \n                           2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"1062_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. \n                           6, pl1 (2013).","journal-title":"Sci. Signal."},{"key":"1062_CR41","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods \n                           9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"1062_CR42","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1109\/TCBB.2013.2297113","volume":"11","author":"M Amit","year":"2014","unstructured":"Amit, M. et al. Local exact pattern matching for non-fixed RNA structures. IEEE\/ACM Trans. Comput. Biol. Bioinform. \n                           11, 219\u2013230 (2014).","journal-title":"IEEE\/ACM Trans. Comput. Biol. Bioinform."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01062-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01062-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01062-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T16:47:35Z","timestamp":1671727655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01062-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["1062"],"URL":"https:\/\/doi.org\/10.1038\/s41467-017-01062-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,26]]},"assertion":[{"value":"13 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1136"}}